Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.
about
A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancerBioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics.Recombinant human alpha fetoprotein synergistically potentiates the anti-cancer effects of 1'-S-1'-acetoxychavicol acetate when used as a complex against human tumours harbouring AFP-receptors.Single-antibody, targeted nanoparticle delivery of camptothecin.An update in the use of antibodies to treat glioblastoma multiforme.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.Developments and recent advancements in the field of endogenous amino acid selective bond forming reactions for bioconjugation.A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges.Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.Recombinant nanocomposites by the clinical drugs of Abraxane® and Herceptin® as sequentially dual-targeting therapeutics for breast cancer.Destination Known: Targeted Drug Delivery in Atherosclerosis and Thrombosis
P2860
Q33689021-3515158D-C60C-4119-A80D-C7DC11C83437Q35068522-7584AF1D-479A-42C4-BA2A-E35E85EAD0A8Q35687188-EE0B11A7-A05C-4B45-905C-74707A2B1A26Q37227392-4B90985A-B1A8-4974-9DB5-09EFE1FBC110Q37329927-76ADBC22-39B0-43D9-AEFA-754F96F81D7FQ38489049-2701B5BA-45FC-4146-9B4E-79BCFD3B5DBCQ38497871-759F1CF1-A058-4B10-AA68-93AADF306BADQ38781425-D705E2FA-CA5F-416A-9687-CDE24A6EE845Q38845355-86B4F1E4-B115-4741-8178-F1711F08B11DQ41022992-3A5A1110-DC18-485C-8516-A4A1A6EA11BEQ42939121-D89BC65A-693A-495C-857C-2CCDFE19ACD4Q50333939-6BBDF693-B21D-452E-B01A-E8AE15650D01Q57342839-B34CA259-1DAB-4C23-A124-899A65C47805
P2860
Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Drug conjugates such as Antibo ...... lenge daily clinical practice.
@en
type
label
Drug conjugates such as Antibo ...... lenge daily clinical practice.
@en
prefLabel
Drug conjugates such as Antibo ...... lenge daily clinical practice.
@en
P2860
P921
P356
P1476
Drug conjugates such as Antibo ...... llenge daily clinical practice
@en
P2093
Nathan Cantoni
Wolf-Dieter Janthur
P2860
P304
16020-16045
P356
10.3390/IJMS131216020
P407
P5008
P577
2012-11-28T00:00:00Z